Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 59

1.

Selecting Sensitive Parameter Subsets in Dynamical Models With Application to Biomechanical System Identification.

Ramadan A, Boss C, Choi J, Peter Reeves N, Cholewicki J, Popovich JM Jr, Radcliffe CJ.

J Biomech Eng. 2018 Jul 1;140(7). doi: 10.1115/1.4039677.

PMID:
29570752
2.

A novel approach to determine primary stability of acetabular press-fit cups.

Weißmann V, Boss C, Bader R, Hansmann H.

J Mech Behav Biomed Mater. 2018 Apr;80:1-10. doi: 10.1016/j.jmbbm.2018.01.015.

PMID:
29414463
3.

Encapsulated Optically Responsive Cell Systems: Toward Smart Implants in Biomedicine.

Boss C, Bouche N, De Marchi U.

Adv Healthc Mater. 2018 Apr;7(8):e1701148. doi: 10.1002/adhm.201701148. Epub 2017 Dec 28. Review.

PMID:
29283209
4.

The Screening Compound Collection: A Key Asset for Drug Discovery.

Boss C, Hazemann J, Kimmerlin T, von Korff M, Lüthi U, Peter O, Sander T, Siegrist R.

Chimia (Aarau). 2017 Oct 25;71(10):667-677. doi: 10.2533/chimia.2017.667.

PMID:
29070412
5.

The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468.

Treiber A, de Kanter R, Roch C, Gatfield J, Boss C, von Raumer M, Schindelholz B, Muehlan C, van Gerven J, Jenck F.

J Pharmacol Exp Ther. 2017 Sep;362(3):489-503. doi: 10.1124/jpet.117.241596. Epub 2017 Jun 29.

6.

Orexin research: patent news from 2016.

Boss C, Roch C.

Expert Opin Ther Pat. 2017 Oct;27(10):1123-1133. doi: 10.1080/13543776.2017.1344221. Epub 2017 Jun 28. Review.

PMID:
28631980
7.

Encapsulation of Insulin-Secreting Cells Expressing a Genetically Encoded Fluorescent Calcium Indicator for Cell-Based Sensing In Vivo.

Boss C, De Marchi U, Hermant A, Conrad M, Sizzano F, Palini A, Wiederkehr A, Bouche N.

Adv Healthc Mater. 2017 Feb;6(4). doi: 10.1002/adhm.201600869. Epub 2016 Dec 20.

PMID:
27995762
8.

Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling.

Le Bihan A, de Kanter R, Angulo-Barturen I, Binkert C, Boss C, Brun R, Brunner R, Buchmann S, Burrows J, Dechering KJ, Delves M, Ewerling S, Ferrer S, Fischli C, Gamo-Benito FJ, Gnädig NF, Heidmann B, Jiménez-Díaz MB, Leroy D, Martínez MS, Meyer S, Moehrle JJ, Ng CL, Noviyanti R, Ruecker A, Sanz LM, Sauerwein RW, Scheurer C, Schleiferboeck S, Sinden R, Snyder C, Straimer J, Wirjanata G, Marfurt J, Price RN, Weller T, Fischli W, Fidock DA, Clozel M, Wittlin S.

PLoS Med. 2016 Oct 4;13(10):e1002138. doi: 10.1371/journal.pmed.1002138. eCollection 2016 Oct.

9.

Discovery and Characterization of ACT-451840: an Antimalarial Drug with a Novel Mechanism of Action.

Boss C, Aissaoui H, Amaral N, Bauer A, Bazire S, Binkert C, Brun R, Bürki C, Ciana CL, Corminboeuf O, Delahaye S, Dollinger C, Fischli C, Fischli W, Flock A, Frantz MC, Girault M, Grisostomi C, Friedli A, Heidmann B, Hinder C, Jacob G, Le Bihan A, Malrieu S, Mamzed S, Merot A, Meyer S, Peixoto S, Petit N, Siegrist R, Trollux J, Weller T, Wittlin S.

ChemMedChem. 2016 Sep 20;11(18):1995-2014. doi: 10.1002/cmdc.201600298. Epub 2016 Jul 29.

PMID:
27471138
10.

Discovery of Highly Potent Dual Orexin Receptor Antagonists via a Scaffold-Hopping Approach.

Heidmann B, Gatfield J, Roch C, Treiber A, Tortoioli S, Brotschi C, Williams JT, Bolli MH, Abele S, Sifferlen T, Jenck F, Boss C.

ChemMedChem. 2016 Oct 6;11(19):2132-2146. doi: 10.1002/cmdc.201600175. Epub 2016 Jul 8.

PMID:
27390287
11.

From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective.

Boss C, Bolli MH, Gatfield J.

Bioorg Med Chem Lett. 2016 Aug 1;26(15):3381-94. doi: 10.1016/j.bmcl.2016.06.014. Epub 2016 Jun 10. Review.

PMID:
27321813
12.
13.

Recent trends in orexin research--2010 to 2015.

Boss C, Roch C.

Bioorg Med Chem Lett. 2015 Aug 1;25(15):2875-87. doi: 10.1016/j.bmcl.2015.05.012. Epub 2015 May 15. Review.

PMID:
26045032
14.

Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.

Sifferlen T, Boller A, Chardonneau A, Cottreel E, Gatfield J, Treiber A, Roch C, Jenck F, Aissaoui H, Williams JT, Brotschi C, Heidmann B, Siegrist R, Boss C.

Bioorg Med Chem Lett. 2015 May 1;25(9):1884-91. doi: 10.1016/j.bmcl.2015.03.035. Epub 2015 Mar 21.

PMID:
25838147
15.

Orexin receptor antagonists--a patent review (2010 to August 2014).

Boss C.

Expert Opin Ther Pat. 2014 Dec;24(12):1367-81. doi: 10.1517/13543776.2014.978859. Review.

PMID:
25407283
16.

Structure-activity relationship, biological, and pharmacological characterization of the proline sulfonamide ACT-462206: a potent, brain-penetrant dual orexin 1/orexin 2 receptor antagonist.

Boss C, Roch-Brisbare C, Steiner MA, Treiber A, Dietrich H, Jenck F, von Raumer M, Sifferlen T, Brotschi C, Heidmann B, Williams JT, Aissaoui H, Siegrist R, Gatfield J.

ChemMedChem. 2014 Nov;9(11):2486-96. doi: 10.1002/cmdc.201402258. Epub 2014 Aug 21.

PMID:
25147058
17.

Discovery of substituted lactams as novel dual orexin receptor antagonists. Synthesis, preliminary structure-activity relationship studies and efforts towards improved metabolic stability and pharmacokinetic properties. Part 1.

Sifferlen T, Boller A, Chardonneau A, Cottreel E, Hoecker J, Aissaoui H, Williams JT, Brotschi C, Heidmann B, Siegrist R, Gatfield J, Treiber A, Brisbare-Roch C, Jenck F, Boss C.

Bioorg Med Chem Lett. 2014 Feb 15;24(4):1201-8. doi: 10.1016/j.bmcl.2013.12.092. Epub 2013 Dec 30.

PMID:
24447850
18.

UV-triggered affinity capture identifies interactions between the Plasmodium falciparum multidrug resistance protein 1 (PfMDR1) and antimalarial agents in live parasitized cells.

Brunner R, Ng CL, Aissaoui H, Akabas MH, Boss C, Brun R, Callaghan PS, Corminboeuf O, Fidock DA, Frame IJ, Heidmann B, Le Bihan A, Jenö P, Mattheis C, Moes S, Müller IB, Paguio M, Roepe PD, Siegrist R, Voss T, Welford RW, Wittlin S, Binkert C.

J Biol Chem. 2013 Aug 2;288(31):22576-83. doi: 10.1074/jbc.M113.453159. Epub 2013 Jun 10.

19.

Structure-activity relationship studies and sleep-promoting activity of novel 1-chloro-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 2.

Sifferlen T, Koberstein R, Cottreel E, Boller A, Weller T, Gatfield J, Brisbare-Roch C, Jenck F, Boss C.

Bioorg Med Chem Lett. 2013 Jul 1;23(13):3857-63. doi: 10.1016/j.bmcl.2013.04.071. Epub 2013 May 8.

PMID:
23719231
20.

Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist.

Steiner MA, Gatfield J, Brisbare-Roch C, Dietrich H, Treiber A, Jenck F, Boss C.

ChemMedChem. 2013 Jun;8(6):898-903. doi: 10.1002/cmdc.201300003. Epub 2013 Apr 15.

PMID:
23589487

Supplemental Content

Loading ...
Support Center